Merex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Merex

Quick Facts

Property Description
Active Ingredient Methotrexate
Form Solution for Injection
Pharmacological Class Antimetabolite, Immunosuppressant
General Purpose Controlling cell growth and immune system activity
Origin Synthetic

What Type of Medicine is Merex?

Merex is a brand name for the medicine whose active ingredient is methotrexate (MTX). This drug is classified as both an antimetabolite and a potent immunosuppressant, which is a type of chemotherapy agent and a Disease-Modifying Anti-Rheumatic Drug (DMARD). As a synthetic medicine, its use is clinically recognized across different medical specialties. For instance, in treating chronic inflammatory conditions, methotrexate is supported by pharmacological studies as the foundational systemic agent for long-term management. Merex is typically available by prescription only (Rx).

Merex: Composition and Physical Form

Merex is primarily supplied as a single-ingredient solution for injection, intended for parenteral administration, generally administered via a vein, muscle, or under the skin. The formulation focuses entirely on the active pharmaceutical ingredient, methotrexate, dissolved in a sterile liquid base/vehicle suitable for injection. This specialized injectable form is designed to ensure controlled and efficient delivery, which is critical for maximizing its systemic effect in patients.

What is the General Goal of Merex?

The general goal of Merex is to modulate the body’s functions by directly interfering with processes that drive rapid cell multiplication and immune activity. This action operates by disrupting folate metabolism, a process cells need to build DNA. This targeted mechanism allows it to suppress the overactive growth of immune cells that cause inflammation, or to halt the uncontrolled multiplication of certain cancer cells. The drug is recognized as an essential medicine due to its efficacy against diseases characterized by excessive cell proliferation or immune activity.

Regulatory References

  1. Methotrexate: MedlinePlus Drug Information

What side effects are possible with Merex?

The official safety profile for Merex (Methotrexate) is formally documented by government regulatory bodies (such as the FDA and EMA) to classify potential adverse reactions based on their frequency and the body system affected.

Adverse Reaction Scope

The most frequent adverse reactions are categorized as follows:

Classification Examples of Documented Effects System-Organ Classes Involved
Very Common (in 1/10) Stomatitis, nausea, vomiting, abdominal distress, elevated liver transaminases. Gastrointestinal Disorders, Hepatobiliary Disorders
Common (in 1/100) Leukopenia, headache, fatigue/malaise, diarrhea, alopecia (hair loss), rash. Blood and Lymphatic System, Nervous System, Skin Disorders

Serious Adverse Reactions and Safety Constraints

Specific, clinically significant risks are explicitly highlighted in the regulatory labeling:

  • Serious Adverse Reactions: These include severe Myelosuppression (bone marrow suppression), Pulmonary Toxicity (e.g., interstitial pneumonitis), and severe Hepatotoxicity (leading to potential fibrosis or cirrhosis).
  • Population-Specific Constraints: The medicine is contraindicated in cases of severe hepatic impairment and during pregnancy due to the risk of fetal harm. Toxicity risk is increased for patients with renal impairment and in older adults.
  • Exposure-Related Patterns: Regulatory documents note that effects like stomatitis and nausea may appear more frequently during the start of treatment, while severe liver toxicity is primarily associated with prolonged, cumulative long-term exposure.

The overall regulatory safety summary structures the understanding of risks by defining the spectrum and likelihood of adverse reactions and by explicitly stating non-usage criteria for specific patient populations and pre-existing conditions.

Overdose and Emergency Response

Overdose Manifestations and When to Seek Help

Overdose with Merex (Methotrexate) is formally documented in government regulatory sources and may result in potentially fatal toxicities, primarily affecting the blood and digestive systems. Documented manifestations include severe bone marrow suppression, which presents as low counts of white blood cells (leucopenia), platelets (thrombocytopenia), and all blood cell lines (pancytopenia).

Severe gastrointestinal toxicity is a critical sign, with symptoms like diarrhea and ulcerative stomatitis (mouth sores). These manifestations are specifically listed as requiring the immediate interruption of therapy to mitigate the risk of severe outcomes, such as intestinal perforation. Acute damage to the renal system (acute renal failure) and the hepatic system (hepatotoxicity) are also documented findings that impair the drug's elimination.

Emergency Response and Specific Antidote

Regulatory guidance mandates that patients must seek urgent medical attention immediately upon suspicion of overdose or observation of initial severe signs. The official prescribing information defines the specific antidote for Merex as leucovorin (calcium folinate), which must be administered promptly to counteract hematopoietic effects. Supportive care procedures described include alkalinisation of the urine and hydration to prevent the precipitation of the drug in the kidneys. Additionally, delayed elimination, often seen in patients with impaired renal function or fluid accumulation (ascites), increases the risk of toxicity and requires closer monitoring and specialized management.

Therapeutic Uses of Merex

Merex is commonly used to help with symptomatic support across three primary therapeutic domains. The medication is used in conditions marked by heightened symptoms, such as rheumatoid arthritis (RA), severe psoriasis, polyarticular juvenile idiopathic arthritis (pJIA), and specific cancers (leukemias and lymphomas).

Management of Chronic Autoimmune Diseases

Merex is commonly used to help with the management of severe chronic conditions like RA, psoriatic arthritis, and pJIA. It is applied when these conditions are characterized by symptoms related to physical discomfort, such as pronounced, persistent joint inflammation, swelling, and disabling stiffness, which is often challenging to manage. The primary benefit is that the medication may assist with maintaining functional stability and contributes to easing distress related to mobility.

Treatment of Severe Proliferative Skin Conditions

The medication is commonly used to help with severe, widespread psoriasis when the condition presents with thick, scaling skin lesions. It addresses symptom clusters that create noticeable physiological strain. This use is considered relevant for easing the overall symptom burden.


Quick Fact: Relief for Chronic Inflammation

Property Description
Symptom Domain Joint swelling, stiffness, and pain
Benefit Focus Supports functional stability and eases distress
Conditions Used In Severe Rheumatoid Arthritis, Psoriatic Arthritis
Use Context Long-term systemic management

Eligibility and Restrictions for Use

Who can and cannot use Merex?

This medication is not suitable for all patients. Eligibility for treatment is strictly defined by official regulatory labeling, primarily concerning allergic history and patient-specific conditions.

Populations Not Eligible or Restricted

Classification Population/Condition Restriction Basis
Contraindicated History of severe hypersensitivity to meropenem or any component. Allergic history
Contraindicated History of anaphylactic reactions to any beta-lactam antibiotic class (e.g., penicillin). Allergic history
Not Indicated Pediatric patients younger than 3 months of age. Age threshold (use not established)
Use Restricted Patients with renal impairment (creatinine clearance leq 50 mL/min). Requires dose reduction
Not Recommended Concomitant use with valproic acid/divalproex sodium. Risk of reduced valproic acid concentration

Use is generally allowed for adult patients who do not meet any criteria for contraindication, non-recommendation, or severe restriction, and for pediatric patients aged three months and older for indicated conditions. Eligibility for use must be confirmed by a healthcare provider.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Merex

Property Description
Medicinal product categories with documented interactions NSAIDs, Salicylates, Antibiotics (Penicillins, Sulphonamides), Anti-gout agents (Probenecid), Folate Antagonists (Trimethoprim), Other Immunosuppressants (Leflunomide), Proton Pump Inhibitors (PPIs), Live Attenuated Vaccines, Alcohol.
Specific interacting medicines (if explicitly listed) Probenecid, Trimethoprim, Co-trimoxazole, Penicillins, Sulphonamides, Leflunomide, Salicylates (high-dose), Alcohol.
Mechanistic basis of interactions Inhibition of Renal Tubular Secretion: Documented for NSAIDs and Probenecid, resulting from competition for Organic Anion Transporters (OATs). Additive Toxicity: Documented for other myelosuppressive or hepatotoxic agents. Additive Antifolate Effect: Documented for other folate antagonists.
Population-specific interaction notes The risk and severity of exposure-altering interactions are significantly heightened in patients with impaired renal function or in the elderly due to reduced baseline clearance.

Official Interaction Statements:

  • Co-administration with NSAIDs and Probenecid is formally documented to increase methotrexate plasma concentrations and reduce its renal clearance through the inhibition of renal tubular secretion.
  • The combination with Folate Antagonists (e.g., Trimethoprim) is officially classified as an additive antifolate effect, which increases the documented risk of severe hematological toxicity.
  • Concurrent consumption of Alcohol is officially documented to increase the risk of hepatotoxicity due to an additive toxic load on the liver.
  • Live Attenuated Vaccines are generally considered contraindicated in patients receiving immunosuppressive doses due to the officially recognized risk of disseminated infection.

Connection to the overall interaction profile

Regulatory documents define Methotrexate’s interaction structure by highlighting interactions that interfere with its elimination via renal transporters and those that pose an additive toxicity risk to the bone marrow and liver. These documented pharmacokinetic and pharmacodynamic interactions establish the official foundation for restrictions associated with co-administering the drug with other medicines or alcohol.

Mechanism of Action

Merex, containing methotrexate (MTX), acts through two core mechanistic pathways to modulate biological processes, resulting in the suppression of cell proliferation and the modulation of inflammatory signaling.

Antimetabolite Action: Blocking Cell Proliferation

This mechanism centers on the competitive inhibition of Dihydrofolate Reductase (DHFR). By binding to DHFR, Merex limits the cofactors required for making the building blocks of DNA and RNA, thereby suppressing the rapid multiplication of highly active immune cells like T-lymphocytes, which are highly active components of immune responses.

Immunomodulation via Adenosine Signaling

The drug also engages a secondary pathway by indirectly increasing the release of extracellular adenosine. This signaling molecule then activates specific cell surface receptors (A2A and A3), which act to inhibit the secretion of key pro-inflammatory mediators, such as TNF-alpha and Interleukin-6 (IL-6), leading to the physiological modulation of systemic inflammatory responses.

Mechanism Constraints and Time-Dependent Effect

The full biological consequence of Merex requires the gradual formation and accumulation of active polyglutamate forms inside the target cells. This time-dependent process is why a sustained level of the drug is needed for weeks to establish and maintain the suppressive and modulatory physiological state.

Dosage and Administration Information

How Merex is Used: Official Administration Guidelines

Merex is the brand name for methotrexate, supplied as a solution for injection. Its use follows established standards to ensure proper administration for its approved conditions.

Approved Routes and Schedules

Administration routes are determined by the specific clinical context. For the injectable form, official routes include Intramuscular (IM), Subcutaneous (SC), Intravenous (IV), Intra-arterial, and Intrathecal (IT).

For chronic inflammatory diseases like rheumatoid arthritis and psoriasis, administration must adhere to a strict once-weekly schedule to avoid serious complications from accidental daily dosing.

Standard Dosing Regimens (Non-Oncology)

Dosing follows established ranges, which should not be exceeded:

Indication Starting Dose Maximum Weekly Dose
Rheumatoid Arthritis (RA) 7.5 mg once weekly (IM/SC) 20 mg once weekly
Severe Psoriasis 10 mg to 25 mg once weekly 30 mg once weekly

The dosage for Polyarticular Juvenile Idiopathic Arthritis (pJIA) is typically calculated as 10 mg/m^2 once weekly (SC/IM).

Special Procedural Requirements

Administration must be overseen by a physician experienced in this type of therapy. Certain procedures require specific conditions:

  • Intrathecal Use: Requires a preservative-free formulation to be diluted before injection into the spinal fluid.
  • Organ Function Adjustment: Doses must be reduced in patients with impaired renal (kidney) function due to reduced drug clearance.
  • High-Dose Protocols: Intravenous high-dose regimens must be followed by mandatory leucovorin rescue based on monitored drug levels.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Merex (Methotrexate)

This section provides a summary of the official research evidence and study landscape for Merex, focusing on clinical evaluation findings as reported in authoritative sources. This overview remains a non-advisory, patient-friendly summary of the available research, describing what has been studied and what remains uncertain.


Evidence from Studies in Rheumatoid Arthritis (RA)

The evidence base for Merex in adult Rheumatoid Arthritis is well-established through many high-quality Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. Studies explored the drug's use both alone (monotherapy) or as part of a combination treatment.

Studies focused on several objective and subjective measurements related to disease activity. The main outcomes related to systemic or functional imbalance that were monitored included standard criteria to assess disease activity (like the ACR response criteria), as well as changes in the counting of tender and swollen joints. Evidence quality for this indication is categorized as High based on scientific review.


Evidence from Studies in Severe Psoriasis

Research for Merex in severe psoriasis comes from a mix of Randomized Controlled Trials and data collected through large-scale Observational and Retrospective Cohort Studies. The main outcomes studied involved measurement of outcomes related to subjective patient experience and skin condition severity, such as standardized scoring of the extent and thickness of lesions (PASI scores).


Evidence from Studies in Pediatric and Oncologic Conditions

Research has explored the role of Merex in managing conditions in children and young adults, as well as in multi-agent oncologic treatment protocols. For Polyarticular Juvenile Idiopathic Arthritis (pJIA), studies examined outcomes related to patient-reported experience using specialized criteria (ACR Pedi response scores). In the oncologic setting, the drug is evaluated as a required component of complex, multi-drug chemotherapy regimens in large-scale, long-term RCTs, monitoring overall survival (OS) and event-free survival (EFS) metrics.


Research Gaps and Areas of Uncertainty

While a large body of evidence exists, researchers have identified areas where data remains insufficient. Comparative evidence is lacking to reliably predict which individual patient will respond to Merex, as research describes group patterns and findings do not serve as individual predictions. Data for certain patient groups, such as older adults with significant medical conditions, remain insufficient, and comparative evidence for evaluating long-term patterns against newer biologic agents is also lacking.

Key Studies & References

  1. Network Meta-Analysis Validates the Use of Methotrexate in RA Compared With Other Treatments
  2. Methotrexate Management in Psoriasis: Are We Following the Guidelines? (Used for PASI 75 outcomes and RCT context)
  3. Genetic determinants for methotrexate response in juvenile idiopathic arthritis (Focuses on pJIA and individualized response/SNPs)

Frequently Asked Questions (FAQ)

Common questions about Merex (FAQ)


Q: What symptoms is Merex intended to help manage?

Merex is officially indicated for treating chronic inflammatory conditions, such as severe rheumatoid arthritis (RA) and psoriasis. For RA, official documents indicate it helps reduce the symptoms of pain and swelling. For psoriasis, it is used to control severe, uncontrolled skin lesions.


Q: Does official evidence indicate Merex causes changes in weight (gain or loss)?

Unusual weight loss is listed in regulatory documents as a symptom that may be associated with more serious adverse reactions, particularly potential liver injury. Weight loss is not specifically listed as a common, non-serious side effect in the official frequency tables.


Q: Can Merex affect a person's sleep patterns?

Yes, drowsiness is listed in the official product information as a potential side effect that may occur while using Merex.


Q: Are there any specific foods or dietary supplements that can interact with Merex?

Official regulatory documents contain a strong warning against concurrent alcohol consumption due to a documented increase in the risk of hepatotoxicity (liver damage). However, there is no documented interaction between Merex and grapefruit or grapefruit juice.


Q: Are there any signs of liver or kidney problems to watch out for while taking Merex?

Yes, regulatory labeling describes signs of serious toxicity. Signs of liver problems can include yellowing of the skin or eyes, and pain in the upper right part of the stomach. Signs of kidney problems can include a noticeable decrease or increase in urination or swelling of the extremities.


Q: Does Merex interact with birth control pills or other hormonal medications?

Due to the severe risk of fetal harm, regulatory guidance requires the use of effective contraception for patients who are able to become pregnant while receiving treatment with Merex. There are no specific warnings listed about interactions that reduce the effectiveness of hormonal contraceptives.


Q: Is there any information about Merex interactions with grapefruit or grapefruit juice?

According to official information and clinical guidelines, there is no documented interaction between grapefruit juice and the active ingredient in Merex.


Q: Does smoking affect how Merex works in the body?

Studies and official information indicate that smoking may have an impact on the drug's effectiveness. Research suggests that current smoking significantly reduces the expected clinical benefit of methotrexate in patients with Rheumatoid Arthritis.


Q: What is the generally described procedure if a person misses a single dose of Merex?

Because Merex is administered on a strict weekly schedule, the product information states that if a dose is missed, individuals should seek advice from a healthcare professional, especially if the dose is more than two days late. Regulatory guidance indicates that a healthcare professional should be contacted for advice in this situation, and it is strictly advised never to take two doses together.


Q: How does Merex affect the central nervous system?

Documented effects on the nervous system include common issues like headache, dizziness, and drowsiness. Serious effects reported in regulatory documents include blurred vision, seizures, and states of confusion.


Q: Are there known effects of Merex on mental clarity or ability to drive?

Official information lists side effects such as drowsiness and dizziness. Because the drug can affect the central nervous system and cause temporary mental changes, regulatory warnings note that caution may be necessary when driving or operating heavy machinery.


Q: Do the side effects of Merex get worse over time?

The pattern of side effects varies depending on the specific reaction. Regulatory documents note that effects like severe liver toxicity are primarily associated with prolonged, cumulative long-term exposure. Conversely, other common effects like nausea may appear more frequently during the initial start of treatment.


Q: What is the difference between common and serious side effects of Merex?

Regulatory documents classify side effects based on frequency and severity. Common side effects are generally mild and occur more often (e.g., nausea or headache). Serious side effects occur less frequently but are clinically significant, sometimes requiring immediate medical assessment.


Q: Can Merex cause changes in blood sugar levels?

Some regulatory documents list diabetes as a rare reaction attributed to the use of methotrexate. The relationship between the drug and changes in blood glucose levels is complex and not fully defined.


Q: Is it described that taking Merex with food or on an empty stomach makes a difference?

For the oral formulation of the active ingredient, regulatory sources generally state that it can be taken either before or after food, depending on the specific product formulation.


Q: Is Merex associated with any vision changes or problems?

Yes, common side effects can include reddened eyes. Serious side effects include blurred vision or sudden loss of vision, which are clinically significant and described in regulatory guidance.


Q: Are there restrictions on who can use Merex based on age (children or the elderly)?

The medicine is not indicated for pediatric patients younger than 3 months of age. Regulatory documents also note that the risk of toxicity is increased in older adults due to the increased risk of toxicity, requiring careful management.


Q: Is Merex only prescribed by specialists?

The official product information specifies that administration must be overseen by a physician who is experienced in this type of therapy. This indicates that experienced prescribing and monitoring are necessary for its use.


Q: Is Merex available in a generic version, and is it considered medically equivalent?

Methotrexate is the active ingredient, and Merex is a brand name. Generic formulations are regulated by authorities to ensure they contain the same active ingredient and are considered therapeutically equivalent to the brand name product.


Q: What are the ingredients in Merex besides the active medication (excipients)?

The active ingredient is methotrexate. The full list of excipients (inactive ingredients), such as stabilizers and the liquid base, is provided in the official regulatory documentation (e.g., SmPC) for the specific formulation.


Q: Are there any non-serious, but common, lifestyle issues associated with taking Merex (e.g., dry mouth)?

The most common non-serious effects listed include stomatitis (soreness or inflammation of the mouth), nausea, and headache. These effects are typically classified as non-serious.


Q: What is the expected duration of action for one dose of Merex?

Merex is administered on a strict once-weekly schedule. The therapeutic effect requires the gradual accumulation of the drug within cells, meaning the weekly dose is designed to sustain the necessary therapeutic level of the drug until the next scheduled dose.


Q: Can people with kidney or liver impairment use Merex, and what are the general considerations?

Use is strictly contraindicated in cases of severe hepatic (liver) impairment. For renal (kidney) impairment, a dose reduction is required due to reduced drug clearance, and the overall toxicity risk is significantly increased.


Q: Does Merex carry a specific warning about use with other medications that cause drowsiness?

The drug itself can cause side effects like drowsiness and dizziness. Therefore, caution is generally warranted when co-administering Merex with any other medication that may also cause central nervous system depression.

How should Merex be stored and disposed of?

Storage and Disposal Conditions for Merex

Merex (methotrexate) injection requires specific storage conditions to maintain its stability and effectiveness, as mandated by regulatory labeling. The product must be stored at a temperature not exceeding 25 C (77 F) and must not be frozen.

Required Storage and Protection

The injection must be stored in its original container to ensure protection from light. It is mandatory that the medicine be kept out of the sight and reach of children at all times.

Disposal Instructions

Methotrexate is classified as a cytotoxic/hazardous medicinal product. Used and unused Merex and its related waste materials, such as syringes, must not be placed in household trash or poured down the drain. All disposal must follow local regulatory requirements for cytotoxic waste handling. Return expired or unused product to a pharmacist or official disposal program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Merex found in:

A-Z Index: